Anti-complement factor H (CFH) autoantibodies could delay pristane-induced lupus nephritis.

[1]  John D Lambris,et al.  Complement‐targeted therapeutics: An emerging field enabled by academic drug discovery , 2023, American journal of hematology.

[2]  E. Goicoechea de Jorge,et al.  The Factor H protein family: The switchers of the complement alternative pathway , 2022, Immunological reviews.

[3]  Sumedha Bagga,et al.  Anti-factor H antibody and its role in atypical hemolytic uremic syndrome , 2022, Frontiers in Immunology.

[4]  Xin Dang,et al.  Lupus nephritis: new progress in diagnosis and treatment. , 2022, Journal of autoimmunity.

[5]  T. Cavero,et al.  C3 glomerulopathy associated with monoclonal gammopathy: impact of chronic histologic lesions and beneficial effects of clone-targeted therapies. , 2021, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  O. Monticielo,et al.  Lupus animal models and neuropsychiatric implications , 2020, Clinical Rheumatology.

[7]  Min Chen,et al.  Anti-Complement Factor H Autoantibodies May Be Protective in Lupus Nephritis. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[8]  Jie Ding,et al.  Immunological features and functional analysis of anti-CFH autoantibodies in patients with atypical hemolytic uremic syndrome , 2018, Pediatric Nephrology.

[9]  T. Stehle,et al.  Biophysical analysis of sialic acid recognition by the complement regulator Factor H , 2018, Glycobiology.

[10]  T. Niki,et al.  Role of Lgals9 Deficiency in Attenuating Nephritis and Arthritis in BALB/c Mice in a Pristane‐Induced Lupus Model , 2018, Arthritis & rheumatology.

[11]  J. Cesbron,et al.  Autoantibodies Targeting Ficolin‐2 in Systemic Lupus Erythematosus Patients With Active Nephritis , 2018, Arthritis care & research.

[12]  M. Ehlers,et al.  Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways , 2018, Front. Immunol..

[13]  G. Gilliland,et al.  Human IgG subclass cross-species reactivity to mouse and cynomolgus monkey Fcγ receptors. , 2018, Immunology letters.

[14]  G. Xing,et al.  Tubular basement membrane immune complex deposition is associated with activity and progression of lupus nephritis: a large multicenter Chinese study , 2018, Lupus.

[15]  P. Böelle,et al.  Association between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients with Systemic Lupus Erythematosus , 2016, PloS one.

[16]  S. Meri.  Self‐nonself discrimination by the complement system , 2016, FEBS letters.

[17]  E. Daugas,et al.  Protective role of mouse IgG1 in cryoglobulinaemia; insights from an animal model and relevance to human pathology. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  R. Quigg,et al.  Complement in Lupus Nephritis: New Perspectives , 2015, Kidney Diseases.

[19]  T. Jokiranta,et al.  Anti–Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases , 2015, The Journal of Immunology.

[20]  Ming-hui Zhao,et al.  Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro. , 2014, Immunobiology.

[21]  Ming-hui Zhao,et al.  A method of purifying intact complement factor H from human plasma. , 2013, Protein expression and purification.

[22]  Feng Yu,et al.  Serum complement factor H is associated with clinical and pathological activities of patients with lupus nephritis. , 2012, Rheumatology.

[23]  A. Blom,et al.  Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome , 2012, Arthritis Research & Therapy.

[24]  R. Quigg,et al.  Complement factor H deficiency accelerates development of lupus nephritis. , 2011, Journal of the American Society of Nephrology : JASN.

[25]  H. Cook,et al.  Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. , 2010, Kidney international.

[26]  P. Galle,et al.  Interleukin 6 (IL-6) Deficiency Delays Lupus Nephritis in MRL-Faslpr Mice: The IL-6 Pathway as a New Therapeutic Target in Treatment of Autoimmune Kidney Disease in Systemic Lupus Erythematosus , 2010, The Journal of Rheumatology.

[27]  C. Suh,et al.  Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus , 2007, Journal of Clinical Immunology.

[28]  Xiao-yu R. Song,et al.  Anti‐interleukin‐6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus , 2006, Immunology.

[29]  S. Izui,et al.  Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies , 2006, Springer Seminars in Immunopathology.

[30]  S. K. George,et al.  Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. , 2006, Cytokine.

[31]  Y. Shoenfeld,et al.  Protective Molecules–C-Reactive Protein (CRP), Serum Amyloid P (SAP), Pentraxin3 (PTX3), Mannose-Binding Lectin (MBL), and Apolipoprotein A1 (Apo A1), and Their Autoantibodies: Prevalence and Clinical Significance in Autoimmunity , 2005, Journal of Clinical Immunology.

[32]  P. Zipfel,et al.  Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  P. Zipfel,et al.  Mapping of the domains required for decay acceleration activity of the human factor H‐like protein 1 and factor H , 1996, European journal of immunology.

[34]  J. Tranum-Jensen,et al.  Hereditary, Complete Deficiency of Complement Factor H Associated with Recurrent Meningococcal Disease , 1989, Scandinavian journal of immunology.

[35]  R. Schreiber,et al.  Human complement C3b inactivator: isolation, characterization, and demonstration of an absolute requirement for the serum protein beta1H for cleavage of C3b and C4b in solution , 1977, The Journal of experimental medicine.

[36]  J. Weiler,et al.  Control of the amplification convertase of complement by the plasma protein beta1H. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[37]  M. Bastami,et al.  The role of microbiota in the pathogenesis of lupus: Dose it impact lupus nephritis? , 2019, Pharmacological research.

[38]  E. Klang,et al.  A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different antibodies found in SLE patients. , 2015, Autoimmunity reviews.

[39]  J. Miyazaki,et al.  Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. , 1992, Proceedings of the National Academy of Sciences of the United States of America.